{
    "clinical_study": {
        "@rank": "70321", 
        "arm_group": {
            "arm_group_label": "Mesenchymal stem cell", 
            "arm_group_type": "Experimental", 
            "description": "Procedure: posterior cervical laminectomy and MSC transplantation. After laminectomy, 1.6X107 and 3.2 X107 Autologous MSCs is injected into the intramedullary and intrathecal space respectively"
        }, 
        "brief_summary": {
            "textblock": "This phase II/III clinical trial is designed to evaluate the safety and efficacy of\n      autologous Mesenchymal Stem Cells (MSC) transplanted directly into the injured spinal cord."
        }, 
        "brief_title": "Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Spinal Cord Injury", 
        "condition_browse": {
            "mesh_term": [
                "Spinal Cord Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "The Principal investigator has performed a clinical trial using autologous MSCs in patients\n      with cervical spinal cord injury. The results revealed the safety of autologous MSC. This\n      Phase II, III single-center trial is to assess the safety and efficacy of bone\n      marrow-derived mesenchymal stem cell transplantation direct to injured spinal cord site via\n      laminectomy. After recovery from the operation, the subjects receive 4 weeks of physical and\n      occupational therapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged between 16-65 years\n\n          -  Traumatic spinal cord injury at the level of cervical\n\n          -  American Spinal Injury Association Impairment Scale B\n\n          -  12 months or more post spinal cord injury subject with stable neurological finding\n             after more than 1 month rehabilitation therapy\n\n          -  No signs of contracture\n\n          -  Good physical condition to go through operation\n\n          -  Must be willing and able to participate in study procedures with no mental and verbal\n             problem\n\n          -  Able to consent by patients or legal representatives\n\n        Exclusion Criteria:\n\n          -  Serum SGOT/SGPT > 3 X upper limit of normal or Creatinine > 1.5 X upper limit of\n             normal\n\n          -  Major surgical procedure in the past 3 months\n\n          -  Penetrating injury\n\n          -  Mechanical ventilation\n\n          -  Serious pre-existing medical conditions\n\n          -  Recently diagnosed infection (Urinary tract infection, Pneumonia etc)\n\n          -  Positive skin test for penicillin\n\n          -  Positive result for viral markers (human immunodeficiency virus (HIV), hepatitis B\n             virus (HBV), hepatitis C virus (HCV) and Venereal Disease Research Laboratory (VDRL)\n             test)\n\n          -  Pregnant women, women of childbearing potential who do not want adequate\n             contraception, breastfeeding females\n\n          -  Unwilling to participate in study\n\n          -  Patients with psychiatric disorder severe as to make compliance with the treatment\n             unlike, and signing informed consent impossible\n\n          -  Drug abuse in the past 1 year\n\n          -  Participating in other clinical trials in the past 1 month\n\n          -  Inappropriate patients to participate in the study according to the chief\n             investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01676441", 
            "org_study_id": "Cerecellgram-spine"
        }, 
        "intervention": {
            "arm_group_label": "Mesenchymal stem cell", 
            "intervention_name": "Mesenchymal stem cell transplantation", 
            "intervention_type": "Procedure", 
            "other_name": "cerecellgram-spine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "spinal cord injury", 
            "mesenchymal stem cell"
        ], 
        "lastchanged_date": "August 28, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Songpagu", 
                    "country": "Korea, Republic of", 
                    "state": "Seoul"
                }, 
                "name": "Asan medical center"
            }, 
            "investigator": {
                "last_name": "Sangryong Jeon", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Patients With Chronic Spinal Cord Injury.", 
        "overall_contact": {
            "email": "srjeon@amc.seoul.kr", 
            "last_name": "Sangryong Jeon, MD, PhD", 
            "phone": "82-2-3010-3562"
        }, 
        "overall_contact_backup": {
            "email": "yunbe@hanmail.net", 
            "last_name": "Junghee Shin", 
            "phone": "82-2-3010-6503"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Sangryong Jeon, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Motor Score of the American Spinal Injury Association (ASIA) scale", 
            "safety_issue": "No", 
            "time_frame": "12months"
        }, 
        "reference": {
            "PMID": "22127044", 
            "citation": "Park JH, Kim DY, Sung IY, Choi GH, Jeon MH, Kim KK, Jeon SR. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans. Neurosurgery. 2012 May;70(5):1238-47; discussion 1247. doi: 10.1227/NEU.0b013e31824387f9."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01676441"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Sensory score of the American Spinal Injury Association (ASIA) scale", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Motor Evoked Potentials, Somatosensory Evoked Potentials", 
                "measure": "Electromyogram and Electroneurophysiologic test", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "MRI and Diffusion Tensor Imaging of spinal cord", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Pharmicell Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmicell Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}